Observing high-risk smoldering myeloma patients for insights

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to define the natural history of high-risk smoldering myeloma in a modern cohort of patients. Participants will undergo active surveillance with diffusion weighted whole body magnetic resonance imaging (MRI) to monitor their condition closely. The study focuses on patients diagnosed with high-risk smoldering myeloma, as defined by specific clinical criteria. By tracking these patients over time, the study seeks to gather valuable data on disease progression and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult subject aged ≥ 18 years.
* Diagnosis of smoldering myeloma as per the IMWG criteria, specifically:

  * Serum monoclonal protein (IgG or IgA) of 30g/L or greater per 24 hours or urinary monoclonal protein of 500mg or greater per 24 hours and/or
  * Clonal bone marrow plasma cells 10-59% with the absence of myeloma-defining events or amyloidosis
* High-risk smoldering myeloma defined as two or more out of four of the following criteria:

  * M-spike greater than 2 g/dL
  * An involved/uninvolved free light chain ratio greater than 20
  * Bone marrow plasmacytosis greater than 20%
  * Presence of any of translocation (4;14), deletion 17p, deletion 13q or 1q gain by conventional cytogenetics/fluorescence in situ hybridization (FISH) studies) and/or
  * An IMWG SMM score of 9 or greater according to the IMWG risk model for smoldering multiple myeloma (SMM)
* Diagnosis of high-risk SMM made within 365 days of enrollment in the study. Note: If a patient previously had MGUS or low/intermediate SMM- the date at which high-risk SMM was diagnosed would have to be within 365 days of enrollment in the study.

Exclusion Criteria:

* Presence of any features that would meet diagnostic criteria for myeloma as per the IMWG Criteria
* Presence of extramedullary plasmacytomas
* Presence of any focal bone marrow lesions, or lytic bone lesions on imaging done prior to screening or on screening. However, presence of diffuse or patchy infiltration of the marrow (without any clear lesions) on MRI, will not be an exclusion criteria. Patients with 1 focal marrow lesion on MRI that is attributable to plasma cell dyscrasia, will be excluded from study, even if they do not meet criteria for myeloma. Patients with 1 focal marrow lesion can only be enrolled if the lesion does not appear to be related to myeloma, based on the judgement of the investigator. Use of restricted diffusion and ADC values can assist in ascertainment.
* Creatinine clearance of less than 40ml/min.
* Presence of AL Amyloidosis (the amount of workup necessary to exclude AL Amyloidosis is per the discretion of the treating investigator, however the investigator must attest that they do not believe AL Amyloidosis to be present at time of enrollment. Serum nt-PROBNP is recommended as part of evaluation in order to ascertain for cardiac amyloidosis).

Note: The Hgb cut-offs can vary between institutions (lower cut-off for Hgb University of Utah for men is a Hgb of 14.8, rendering a patient with Hgb of 12.7 as having a CRAB feature). If the Hgb is above 10g/dl but the patient meets the definition of anemia according to the IMWG criteria, by virtue of this being more than 2 g/dl below the limit of normal, the investigator can decide whether to call a patient being considered for screening as having multiple myeloma OR smoldering myeloma and allow enrollment on this study.

Given that the values used to define high-risk SMM can change, at time of enrollment, if utilizing at least 2/4 of the 2/20/20+cytogenetics criteria to enroll, participants should meet at least 2/4 of the 2/20/20. If participants had met at least 2/4 previously at some timepoint but do not meet at least 2/4 currently, they cannot be enrolled in the study.

Where it's running

• Huntsman Cancer Institute at the University of Utah
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Principal investigator: Ghulam Rehman Mohyuddin, MD — Huntsman Cancer Institute
• Study coordinator: Sharmilee Nuli
• Email: Sharmilee.Nuli@hci.utah.edu
• Phone: 801-585-0255

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prolonged overnight fasting combined with a Mediterranean-style diet for people with multiple myeloma or precursor conditions

  This program will test whether longer overnight fasting paired with a Mediterranean-style eating plan is doable for adults with MGUS, smoldering myeloma, or newly diagnosed multiple myeloma who are starting treatment.

  Recruiting University of Miami · Miami, Florida · NCT07446777

• Using Whole Body MRI to Improve Cancer Detection

  This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.

  Recruiting at 2 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Bologna, BO and 2 other locations · NCT06895291

• Combining JNJ-79635322 with Daratumumab or Pomalidomide for Multiple Myeloma Treatment

  This study is testing a new drug called JNJ-79635322 combined with either daratumumab or pomalidomide to see how safe and effective it is for people with multiple myeloma.

  Recruiting at 16 sites Phase 1 Janssen Research & Development, LLC · Denver, Colorado and 15 other locations · NCT06768489

• Network for early diagnosis and management of AL amyloidosis in Italy

  This study is trying to set up a network in Italy to help doctors find AL amyloidosis earlier in patients who are at risk, so they can get treatment sooner and improve their health.

  Recruiting at 4 sites Fondazione IRCCS Policlinico San Matteo di Pavia · Bari and 3 other locations · NCT06383143

• Screening for AL Amyloidosis in patients with Smoldering Multiple Myeloma

  This study is trying to find out if screening for a specific type of amyloidosis can help catch it early in patients with smoldering multiple myeloma before they show any symptoms.

  Recruiting at 12 sites Tufts Medical Center · Birmingham, Alabama and 12 other locations · NCT06365060

• Collection and analysis of biological samples from patients with multiple myeloma and related conditions

  This study is collecting and storing blood samples from patients with multiple myeloma and similar conditions to help researchers learn more about these diseases and improve treatments.

  Recruiting at 41 sites European Myeloma Network B.V. · Melbourne and 40 other locations · NCT06237803

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.